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Abstract
Background: Aim of this review is to focus the attention on people living with HIV infection at risk of developing a
cardiovascular event. What is or what would be the most suitable antiretroviral therapy? Which statin or fibrate to
reduce the risk? How to influence behavior and lifestyles?
Discussion: Prevention of cardiovascular disease (CVD) risk remains the first and essential step in a medical intervention
on these patients. The lifestyle modification, including smoking cessation, increased physical activity, weight reduction,
and the education on healthy dietary practices are the main instruments.
Statins are the cornerstone for the treatment of hypercholesterolemia. They have been shown to slow the progression or
promote regression of coronary plaque, and could also exert an anti-inflammatory and immunomodulatory effect.
However the current guidelines for the use of these drugs in general population are dissimilar, with important differences
between American and European ones. The debate between American and European guidelines is still open and, also
considering the independent risk factor represented by HIV, specific guidelines are warranted.
Ezetimibe reduces the intestinal absorption of cholesterol. It is effective alone or in combination with rosuvastatin. It does
not modify plasmatic concentrations of antiretrovirals. A number of experimental new classes of drugs for the treatment
of hypercholesterolemia are being studied.
Fibrates represent the first choice for treatment of hypertriglyceridemia, however, the renal toxicity of fibrates and statins
should be considered.
Omega 3 fatty acids have a good safety profile, but their efficacy is limited. Another concern is the high dose needed.
Other drugs are acipimox and tesamorelin.
Current antiretroviral therapies are less toxic and more effective than regimens used in the early years. Lipodistrophy and
dyslipidemia are the main causes of long-term toxicities. Not all antiretrovirals have similar toxicities. Protease Inhibitors
may cause dyslipidemia and lipodystrophy, while integrase inhibitors have a minimal impact on lipids profile, and no
evidence of lipodystrophy. There is still much to be written with the introduction of new drugs in clinical practice.
Conclusions: Cardiovascular risk among HIV infected patients, interventions on behavior and lifestyles, use of drugs to
reduce the risk, and switch in antiretroviral therapy, remain nowadays major issues in the management of HIV-infected
patients.
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Background
In the recent years we observed an improvement of sur-
vival and quality of life in people living with HIV
(PLWHIV), due to the success of combined antiretro-
viral treatment (cART) [1].
The early treatment, the reduced toxicity of antiretro-
viral regimens and the fading of thymidine-analogues-
based regimens and the high dosage of ritonavir represent
less atherogenic antiretroviral agents for most PLWHIV.
This is not enough since PLWHIV live longer, thus in
addition to age they add up all degenerative diseases
caused by HIV and the side effects of antiretroviral drugs.
This should encourage physicians and researchers in
seeking the patient’s well-being, not only through
HIV-RNA suppression, but thinking about other more
ambitious goals, perhaps more distant from infectious
diseases.
Aim of this review is to focus the attention on
PLWHIV at risk of developing a cardiovascular event.
What is the most suitable cART? Which statin or fibrate
to use in order to reduce the risk? How to influence be-
havior and lifestyles? Everything in the coming years will
be played in this field, so we must be prepared.
Prevention of cardiovascular events
An inappropriate lifestyle, in particular smoking, re-
duced exercise, unhealthy diet and psychosocial stress
are responsible for an increased CVD risk. The “lifestyle”
is generally based on established patterns of behaviour
over time, which have been internalized from childhood
and adolescence through the interaction of genetic and
environmental factors and that are maintained or even
encouraged by the social context in adulthood age.
The dietary habits and physical activity in particular
are key factors for the reduction of CV diseases: risk fac-
tors such as alcohol use, high blood pressure, high body
mass index, hypercholesterolemia, diabetes, low fruit
and vegetable intake and physical inactivity, collectively
account, with smoking, for more than 60% of cardiovas-
cular deaths globally [2]. Energy intake should be limited
to the amount of energy needed to maintain (or obtain)
a healthy weight, that is a BMI >20.0 but <25.0 kg/m2.
The wide variety of foods of animal and vegetable ori-
gin is the basis for a healthy and balanced diet. Many
published data show that the Mediterranean diet appears
to be protective against cardiovascular disease and total
mortality. The use of this type of diet can have beneficial
effects not only on prevention of the main CVD risk fac-
tors but also on the course of the disease once it pre-
sented. The recommendations of the Mediterranean diet
are reasumed in Table 1.
Smoking remains the main responsible for the majority
of CVD [3]. The 10-year fatal CVD risk is approximately
doubled in smokers. The RR in smokers <50 years of age
is five-fold higher than in non-smokers [4].
Preventing PLWHIV from starting smoking is critical,
because stop smoking remains a formidable challenge. Al-
though the percentage of smokers is declining in Europe,
it still remains high and is rising in women, including ado-
lescents and people socially disadvantaged [5]. Widening
education-related inequalities in smoking cessation rates
have been observed in many European countries. The
risks associated with smoking show a dose-response rela-
tionship with no lower limit for deleterious effects [4].
Duration also plays a role, and while cigarette smoking is
the most common, all types of smoked tobacco, including
low-tar (‘mild’ or ‘light’) cigarettes, filtered cigarettes, ci-
gars and pipes, are harmful [6]. There is no age limit to
the benefits of smoking cessation.
Some studies have investigated how much the increased
mortality in PLWHIV was attributable to smoking. In
2013, a Danish study [7] observed that the cohort of
PLWHIV who smoked had an increased risk of death
from causes non-AIDS related at least four times higher.
A more recent analysis of the same cohort [8] shows that
among HIV people who have never smoked the risk of
heart attack is similar to that of HIV-uninfected subjects;
in contrast, among the HIV active smokers the risk was
three times larger than that observed in HIV negative
smokers. The Danish data can be reproduced in the HIV
population of Western Europe who started an antiretro-
viral treatment. Researchers in the ART Cohort Collabor-
ation [9] analyzed all living patients in antiretroviral
therapy by at least one year, for whom data on smoking
habits were available between January 1999 and December
2008. However, they excluded the intravenous drug users
because in these subjects the habit of smoking is wide-
spread and mortality rates are higher than the rest of the
HIV population. The analysis took into account 17,995 in-
dividuals for a total follow-up of 79,760 person-years. Of
these 60% were smokers. According to the results, the
mortality rate due to all causes was 7.9 (CI 95%: 7.2 to
8.79) per 1000 person-years among smokers and 4.2 (CI
95%: 3.5 to 5.0) among non-smokers.
Finally, it as to be remembered that some ways in
which people cope with stress such as drinking, smoking
or overeating, are not healthy especially in PLWHIV.
Table 1 Main recommendations of the Mediterranean diet [127–131]
Increase the consumption of fresh fruit and vegetables of all kinds
Increase the consumption of legumes such as beans, peas, chickpeas
and lentils
Eat fish two or three times a week
Encourage the use of extra-virgin olive oil and sunflower and maize oils
Limit the consumption of animal saturated fat acids such as butter, lard
and cream
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Combination antiretroviral therapy (cART)
switching
General principles
Switching from current cART to a more lipid-friendly
regimen may represent an option to improve dyslipid-
emia and to reduce cardiovascular risk in PLWHIV. The
principles of cART switching also in the setting of dys-
lipidemia are to maintain virologic suppression, improve
adherence and tolerability [10, 11]. Regimen or single
drug substitution may be done carefully and based on
the review of different patterns: a) individual factors
contributing to dyslipidemia; b) complete clinical and
cART regimens history; c) virologic responses to previ-
ous cART regimens; d) historical genotypic resistance
test; e) adherence history; f ) previous cART associated
toxicities. Besides, influence of current cART regimen
on lipids profile could be evaluated. Clinical trial data on
naïve patients demonstrated that differences antiretro-
viral classes influence lipid values, even if there is het-
erogeneity among agents within every class: ritonavir
(RTV) has been shown to significantly increase plasma
lipid levels, in particular lopinavir/ritonavir (LPV/r) and
fosamprenavir/ritonavir (FPV/r), to lesser extent with
atazanavir/ritonavir (ATV/r) [12, 13].
At the CROI 2017, much attention was centered on the
D.A.D, findings on darunavir (DRV) in regards to the de-
velopment of cardiovascular events. Their analysis had
been based on 7 years of follow-up and linked the cumula-
tive use of DRV/r to a gradually increasing risk of CVD
[14]. CVD incidence with cumulative DRV was similar to
that seen with old-times PIs indinavir and LPV/r. Authors
did not show any clear explanation yet, after indicating
that abnormal lipids did not modify the CVD risk with
DRV/r, and did not provide any distinction between sub-
jects treated with DRV/r BID versus QD.
In the class of nucleoside/nucleotide reverse transcript-
ase inhibitors (NRTIs), dyslipidemia has been associated
with exposure to stavudine, zidovudine and abacavir,
whereas tenofovir disoproxil fumarate (TDF) has been
noted to have a favourable lipid influence [15, 16]. In the
NNRTIs class, efavirenz has been associated with in-
creases in total cholesterol and triglycerides, whereas rilpi-
virine has been shown to have less effect on lipid
parameters than efavirenz [17]. Data on etravirine (ETR)
are limited [18]. The integrase inhibitors (INIs) have a lit-
tle effect on lipid profile [19–21], as well as C-C chemo-
kine receptor type 5 (CCR5) inhibitor (maraviroc) [22].
Since each cART switching has a potential virologic failure
risk, it is recommended to prefer regimens that are sup-
ported by clinical trials, switch studies or observational co-
hort studies. The potential options to appropriately switch
cART agents are listed below:
Switching within NRTIs: there is evidence of improve-
ment of total cholesterol (TC), LDL-C and TGL switching
from abacavir (ABC)/lamivudine to TDF/emtricitabine
(FTC) [23, 24].
Switching from protease inhibitor boosted (PI/r) to
NNRTIs: Most data on effect of switching from PI/r to
nevirapine or efavirenz derived from the early cART era
[25, 26]. In the recent years, the randomized SPIRIT
study, switching from PI/r to rilpivirine (RPV) has been
associated with improved lipid parameters and 10-year
Framingham score [27]. In the ETRASWITCH study the
switch from PI/b to ETR showed a significant reduction
in total cholesterol, TGL and glycemia [28].
Switching from PI unboosted to NNRTI: in a most re-
cent observational trials switch from unboosted PI to
RPV has been associated with significant improved of
lipids parameters [29].
Switching from PI/r to an INSTI: Switching studies
from PI/r to raltegravir (RAL) (SWITCHMRK and
SPIRAL) demonstrated a significant lipid and cardiovas-
cular biomarkers reduction in RAL arm. However, in the
SWITCHMRK study it was noticed an increased risk of
virologic failure that was probably linked to a bias in the
patient’s selection [30, 31]. In the open-label STRATEGY
study, including nearly 433 participants on first- or
second-line treatment regimens with no previous viro-
logic failure, were randomly assigned (2:1) to switch to
elvitegravir/cobicistat (EVG/COBI)/FTC/TDF or con-
tinue stable PI/r regimens. At week 48, gastrointestinal
symptoms improved in the group switched to EVG/
COBI/FTC/TDF. Moreover, the INI based regimens led
to significant decreases in total cholesterol, triglycerides
and HDL-c in LPV/r switches, decrease in triglycerides
in ATV/r switches and increase in HDL-c in darunavir
switches [32].
Switch strategies in antiretroviral therapy in the
management of dyslipidemia
Antiretroviral therapy suppresses viral replication and
reduces the concentration of systemic immune activa-
tion markers [33, 34] and several studies reported the in-
fluence of therapy modification on biomarkers of CVD
(Table 2). On the other hand, multiple evidences suggest
that some antiretrovirals such as the class of PI and the
NRTI abacavir can contribute to the increased cardio-
vascular risk observed among HIV infected subjects
[35]. Protease inhibitors are associated to higher rates of
dyslipidemia and increase of intima-media thickness
[12]. ABC has been initially reported to increase the risk
of myocardial infarction by data coming from the D:A:D
in 2008 [36]. The supposed mechanism is that this drug
can be associated to endothelial disfunction and/or in-
creased platelets activation. Subsequent reports from the
D:A:D study highlighted that abacavir might represent a
risk factor especially for patients presenting other preex-
isting cardiovascular risk factors, but further analyses
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from the Food and Drugs Administration did not link
ABC to increased frequencies of cardiovascular episodes,
thus did not lead to restrictions in the prescription and
use of ABC [37]. Several trials have shown a beneficial
effect of switching to a NNRTI-containing antiretroviral
regimen, as it is shown in Table 3.
Monitoring after switching cART regimen
During the first 3 months after the switch, the patient
should be closely monitored to assess tolerability and
adherence to new cART regimen.
HIV-RNA test may be performed to check for re-
bound viremia 4 weeks after the switch and then every
3 months during the first year; fasting lipids (cholesterol
and triglycerides) should be assessed within 3 months
after the change and every 3 months during the first
year. In absence of new complaints, subsequent moni-
toring should be performed on a regularly scheduled
basis [10, 11].
New antiretroviral drugs and cardiovascular risk
Tenofovir Alefenamide
Tenofovir alafenamide (TAF) is a novel prodrug of tenofo-
vir disiproxil fumarate (TDF). In this new formulations
TAF show higher levels of TDF-DP in periphereal blood
mononuclear cells and lymphoid tissues than TDF. TAF
showed safety advantages compared to TDF containing
regimen regarding bone and renal toxicity [38], regarding
Table 3 Trials on the therapeutic switch to a NNRTI-containing regimen
Study Acronym Study Design and Enrolled Patients Markers evaluated time endpoint
evauation
Laboratory markers change Ref
LIPNEFA
(a subset of NEFA)
A subset (n. 90) of virologically
suppressed HIV-infected patients
enrolled in the NEFA study [98]
enrolled in the NEFA study were
analyzed for the HDL-C and LDL
-C levels in the metabolic and
body-composition substudy
LIPNEFA .
HDL-C and LDL-C
levels
24 At 24 months, efavirenz (EFV) and nevirapine
(NVP) produced similar lipid benefits: HDL-C
levels increased [EFV, 15% (p = 0.001); NVP,
21% (p < 0.001)] and TC to HDL-C ratios
decreased [EFV, 14% (p < 0.001); NVP, 19%
(p < 0.01)].
[25]
SPIRIT Virologically suppressed HIV-
infected adults who were
receiving a PI-based HAART
were switched to emtricitabine-
rilpivirine-tenofovir difumarate
(FTC-RPV-TDF).
TC, LDL-C, TGL,
and TC:HDL-C
ratio.
24 At 24 weeks, levels of TC, LDL-C, TGL, and the
TC:HDL-C ratio had improved significantly in
patients switched to FTC-RPV-TDF compared
to those patients who kept their original PI-
based treatment (p < 0.001). Nevertheless,
HDL-C levels declined significantly less with
the PI-based regimen (p < 0.001).
[17]
Study 111 Virologically suppressed patients
who were switched from EFV-
TDF- FTC to RPV-TDF-FTC.
Fasting TC, LDL-C,
HDL-C, TGL, and
TC:HDL-C ratio.
12, 48 A significative decline in fasting TC, LDL-C and
TGL at 12 weeks into the protocol. Results at
week 48 remained in the same direction
(p = 0.016), although changes from baseline in
HDL-C and the TC:HDL-C ratio were not
significant. The introduction of RPV in the
clinical arena has been very positive for the
patients care, but we all have to remember
the risk of a prolongation of QT interval with
higher doses of this compound (i.e. 75 and
300 mg QD) as seen in the early phases of
clinical development.
[136]
Etraswitch The switch from a PI-containing
regimen to etravirine (ETR) in
patients with therapeutic success.
Glycemia, fasting
TC, LDL-C, HDL-C,
TGL, and TC:HDL-
C ratio.
24 The group of patients who received ETR
showed a significant reduction in TC
(p < 0.001), TGL (p < 0.001), and glycemia
(p = 0.03). The 2 groups differed significantly
in TGL and glycemia at week 24. The greatest
improvement in all lipids was seen in patients
who switched from lopinavir/ritonavir to ETR.
[28]
na A prospective, open-label, 12-week
study of HIV-infected patients
receiving either a on bPI or EFV,
and statin treatment. Four weeks
after statin interruption, bPI or EFV
was switched to ETR (400 mg for 8
weeks) if serum low-density lipoprotein
cholesterol (LDL-C) was ≥3 mM. The
primary endpoint was the proportion
of patients not qualifying for statin
treatment 8 weeks after the ETR switch.
Fasting TC, LDL-C,
HDL-C, TGL, and
TC:HDL-C ratio.
12 After 8 weeks of ETR treatment, 15 patients
(56%) on ETR did not qualify for statin
treatment. After the ETR switch, serum levels
of the cardiovascular biomarkers sICAM and
MCP1/CCL2 decreased by 11.2% and 18.9%,
respectively, and those of CCL5/RANTES and
tissue inhibitor of metalloproteinase-1
increased by 14.3% and 13.4%, respectively,
indicating reduced cardiovascular risk.
[137]
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the lipid profile, increase from baseline in fasting total
cholesterol, LDL cholesterol, HDL and triglycerides were
observed in TAF than with TDF. TAF has no “statin-like”
phenomenon which characterized TDF. Long-term data
are not know.
Cabotegravir
Cabotegravir is an investigational HIV INI drug, cur-
rently being studied in Phase IIb clinical trials. During
preliminary studies conducted on healthy subjects both
in monotherapy and in combination with RPV [39, 40]
no consistent, clinically significant, or dose-related
changes in haematology, clinical chemistry, vital signs,
or ECG abnormalities or trends were observed. Lou et
al. [41], in a study that assessed its effect on cardiac re-
polarization in healthy subjects, demonstrated that cabo-
tegravir at a supratherapeutic dose had no effect on
cardiac repolarization. In a fase IIa study, Spreen et al.
[42] described two cases of laboratory abnormalities in
HIV-1 infected patients in Cabotegravir monotherapy
arm. A subject with type I diabetes had grade 2 hyper-
glycemia at baseline and at all time points other than
day 7 (hypoglycemia) and the follow-up visit (grade 3
hyperglycemia). The other subject, on day 7, had grade 4
TGL elevation subsequent to a very high–fat meal the
previous evening, and TGL were within normal limits at
all other readings. Even the phase IIb studies, LATTE
and LATTE-2 (still ongoing), underlined the good safety
profile of cabotegravir with no cases of ECG abnormal-
ities or metabolic disorders [43].
Doravirine
Doravirine is a NNRTI currently being studied in Phase
III clinical trials as both a single-drug tablet and as part
of a fixed-dose combination tablet. In a preliminary
study with single and multiple doses of doravirine in
healthy subjects, no serious adverse events were re-
ported, and there were no consistent, clinically relevant,
treatment-related effects of doravirine on vital signs or
ECGs. Overall, no clinically significant trends or signals
were observed in laboratory assessments, vital signs or
ECGs [44]. In a randomized, double-blind, placebo-
controlled, short-term monotherapy study of doravirine
Shurmann et al. described no clinically significant abnor-
malities in vital signs, routine blood and urine chemistry
panels, haematology, ECGs, or physical or neurological
examinations in any participant [45]. Results of a phase
IIb clinical trial, presented by Gatell et al. at the 12th
International Congress on HIV Drug Therapy being held
in Glasgow, showed that 6.8% of patients had an in-
crease in total cholesterol and 6.3% an increase of LDL
cholesterol [46].
Pharmacological treatment of dyslipidemia
Drugs for the treatment of hypercholesterolemia
Statins
Statins are the cornerstone of the treatment of hyper-
cholesterolemia. They reduce the synthesis of cholesterol
in the liver by competitively inhibiting the hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase
activity. The reduction in intracellular cholesterol con-
centrations induces LDL receptor expression on the
hepatocyte cell surface, which results in increased ex-
traction of LDL-cholesterol (LDL-C) from the blood and
a decreased concentration of circulating LDL-C and
other lipoproteins including triglycerides-rich particles.
A number of large-scale clinical trials have demon-
strated that statins substantially reduce cardiovascular
(CV) morbidity and mortality in both primary and sec-
ondary prevention [47, 48]. In the general population,
each 1.0 mmol/L (39 mg/dl) reduction in LDL-C level
has been significantly associated with a 10% reduction in
all-cause mortality, largely reflecting significant reduc-
tions in deaths due to coronary heart disease [47].
Meta-analyses of randomized controlled trials that fo-
cused on primary prevention, demonstrated that in
people without established CV disease but with CV risk
factors, the use of statins was associated with signifi-
cantly improved survival and large reductions in the risk
of major CV events [48, 49]. Benefits of statin therapy
were observed in nearly all subgroups, including persons
with diabetes mellitus, men and women, and across age
groups.
The most recent clinical trials suggested that the LDL-C
lowering effect of statins between PLWHIV is similar to
that seen in the general population. Several randomized
studies of hypercholesterolemic HIV-infected patients
showed that LDL-C decreased by 15% to 35% in patients
taking statins as compared with placebo [50]. In a trial in
which PLWHIV on protease inhibitors (PIs) were ran-
domized to atorvastatin 10 mg, rosuvastatin 10 mg, or
pravastatin 20 mg, the mean reductions in the LDL-C at
one year were 20%, 25%, and 18%, respectively, after one
year of therapy [51].
Recently, statins have also been shown to slow the
progression or even promote regression of coronary ath-
erosclerosis in the general population as well as in HIV-
infected patients (Table 4).
Finally, as rosuvastatin has demonstrated to signifi-
cantly reduce several markers of vascular inflammation
and CD4+ and CD8+ T lymphocyte and monocyte acti-
vation in HIV-infected subjects on antiretroviral therapy
[52, 53], statins could exert a wide-reaching anti-
inflammatory and immunomodulatory effect that ex-
tends well beyond CV disease prevention.
Although the effects of statins in HIV-infected patients
are expected to be of a similar magnitude to that has
Maggi et al. BMC Infectious Diseases  (2017) 17:551 Page 7 of 17
been seen in the general population, many issues regard-
ing the use of statins in HIV-infected patients are still
unclear, and further studies are needed to determine
whether statins reduce the number of CV events and
mortality in HIV-infected patients.
The AIDS Clinical Trial network is currently enrolling
in the REPRIEVE (Randomized Trial to Prevent Vascular
Event in HIV) Study, which is a large-scale randomized
trial to investigate daily pitavastatin versus placebo for
the primary prevention of CV events in PLWHIV. Until
the results of such studies specifically conducted in
HIV-infected population will be available, we have to
relay on guidelines for non-HIV-infected patients for the
management of hypercholesterolemia in persons who
are living with HIV.
For the use of statins in CV disease (CVD) prevention,
the European Society of Cardiology and the European
Atherosclerosis Society Guidelines, suggest to evaluate
the total CV risk of the subjects using European SCORE
tables and to identify the LDL-C target for that risk
level. For these guidelines, since the response to statin
treatment is variable, up-titration to reach that target is
mandatory [54].
Differently from European guidelines, the 2013 Ameri-
can College of Cardiology and the American Heart As-
sociation guidelines (ACC/AHA) guidelines introduced a
new risk calculator, and identified four groups of pa-
tients who should be treated with a statin (Table 5) [55].
Current available evidence suggests that the clinical
benefit is largely independent of the type of statin but
depends on the extent of LDL-C lowering; therefore, the
type of statin used should reflect the degree of LDL-C
reduction that is required to reach the target LDL-C in a
given patient [56].
At maximal recommended dose, the different statins
differ in their LDL-C lowering capacity. The ACC/AHA
guidelines classify statin doses by three levels of inten-
sity, based on their ability to lower LDL-C levels in the
general population (Table 6) [55]. On the other hand,
this Expert Panel did not find evidence to support titrat-
ing statin therapy to achieve optimal LDL-C or non-
high-density lipoprotein cholesterol (HDL–C) targets.
Other considerations when deciding about statin ther-
apy include: diabetes mellitus in individual aged less
than 40 years or more than 75 years; a family history of
premature CVD; elevated lifetime risk of CVD; LDL-C
levels of 160 mg/dl or higher; a high sensitivity C-
reactive protein level of 2.0 mg/L or higher; a coronary
artery calcium score of 300 or higher; an ankle-brachial
index below 0.9 [55].
In addition, as HIV-infected patients have been shown
to have an increased risk for CVD compared with the
general population [57], the presence of HIV infection
per se should be considered as an additional risk factor.
The main objection to the ACC/AHA guidelines is
that, if generally adopted, these would result in an in-
creased number of patients treated, potentially at consid-
erable costs. Moreover, the new pooled mixed cohorts
equation used to assess atherosclerotic CVD risk, has
been validated in an American population, different
from European countries and requires more careful
evaluation if applied in other contexts [58]. In summary,
the debate between American and European guidelines
is still open and considering the independent risk factor
represented by HIV, specific guidelines for HIV-infected
persons are warranted.
Statins are generally well tolerated, and serious adverse
events are rare [59]. The most serious adverse effects asso-
ciated with statin therapy is myopathy, which may pro-
gress to rhabdomyolisis, and that, in turn, can lead to a
concomitantly increased risk of renal failure [59]. An ele-
vation of creatine phosphokinase (CK) is the best indicator
of statin-induced myopathy. The common definition of
Table 5 The 2013 ACC/AHA guideline statin benefit group
1) Patients with clinical atherosclerotic CVDa
2) Patients without clinical atherosclerotic CVD, with LDL-C
level ≥ 190 mg/dl
3) Patients aged 40–75 years, with type I or II diabetes mellitus,
and LDL-C level < 190 mg/dl
4) Patients without clinical atherosclerotic CVD or diabetes, aged
40–75 years, with LDL-C < 190 mg/dl, and an estimated 10-year
CV risk ≥ 7.5%b
CVD, cardiovascular disease; CV, cardiovascular
aincluding acute coronary syndrome, myocardial infarction, angina,
revascularization, transient ischemic attack, stroke, peripheral arterial disease
bcalculated using the 2013 ACC/AHA risk assessment tool
Table 4 Effects of statin therapy on the progression of atherosclerosis in HIV- and non-HIV-infected patients
Type of study Method N°of patients Effect of statin therapy Ref
Meta-analysis Coronary VH-IVUS 830 non HIV-infected
patients
Reduction of plaque volume [138]
Randomized double-blind,
placebo controlled trial
FDG-PET of the aorta 40 HIV-infected patients Reduction of plaque volume
and high-risk plaque morphology
over 52 weeks
[139]
Randomized double-blind,
placebo controlled trial
Common carotid
artery IMT
147 HIV-infected patients
on stable ART
Less progression of CCA IMT
over 96 weeks
[52]
VH-IVUS, virtual histology intravascular ultrasound; FDG-PET, Fluorodeoxyglucose-positron emission tomography; IMT, intima media thickness; ART, antiretroviral
therapy; CCA, common carotid artery
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tolerable elevation is a rise of four times the upper limit of
normal (ULN) of this enzyme measured in two occasions
[59]. The incidence of myopathy is low (<1/1000 patients
treated) and the excess risk in comparison with placebo-
treated patients has been <1/10,000 patients treated in
clinical trials. The incidence of rhabdomyolisis associ-
ated with statin therapy is about 1/100.000 per year.
Myopathy is most likely to occur in persons with
complex medical problems and/or who are taking
multiple medications, or in elderly persons, especially
women. Myalgia without CK elevation occurs in 5–10%
of patients in clinical practice [59].
Combination of statins with fibrates may enhance the
risk of myopathy. This risk is greater for gemfibrozil,
and the association of gemfibrozil with statins should be
avoided. The increased risk for myopathy, when com-
bined statins and fibrates seems to be small [60]. The in-
creased risk for myopathy with nicotinic acid has been
debated, but in recent reviews no increased risk of my-
opathy was found with this agent [61].
The increased risk of diabetes with statin is unclear
and high-dose statin are more likely to be associated
with diabetes than lower doses [62]. In a randomized,
placebo-controlled trial of rosuvastatin versus placebo in
antiretroviral treated HIV-infected patients, statin ther-
apy showed a more than 50% increase in insulin resist-
ance, as measured by the homeostasis model assessment
of insulin resistance (HOMA-IR), compared with pla-
cebo. Nevertheless, there were no increase in the inci-
dence of diabetes and no significant change in oral
glucose tolerance testing [63]. The main concern about
the use of statins in HIV-infected patients is represented
by their potential interactions with some antiretrovirals
that may increase the risk of side effects. All current avail-
able statins, except pravastatin, rosuvastatin, and pitavas-
tatin, undergo major hepatic metabolism through the
cytochrome P (CYP) system thus, other pharmacological
substrates of these CYPs may interfere with statin metab-
olism. Conversely, statin therapy may interfere with the
catabolism of other drugs that are metabolized by the
same enzymatic system. PIs and other antiretrovirals, such
efavirenz, interact with statins because they potentially in-
hibit CYP3A4 or transporters or both. The potential inter-
actions with antiretrovirals can be managed with careful
selection of the appropriate statin, often at lower dose
than that is used in the general population [9]. Simvastatin
has greater toxicity when combined with PI-containing
regimens and is contraindicated in PLWHIV on PIs. Prav-
astatin and rosuvastatin generally are considered the safer
statins because their metabolism does not utilize CYP3A4.
Pitavastatin appears to have a particularly favourable phar-
macokinetic profile and is not known to interact with
current available antiretroviral drugs, even in the setting
of PI coadministration [64].
Non-statin drugs for the treatment of hypercholesterolemia
In patients either unable to achieve optimal LDL-C
levels despite statin treatment or intolerant to statin, the
availability of new drugs with LDL-C lowering effects
may be beneficial for reducing atherosclerotic cardiovas-
cular disease (ASCVD) risk.
Ezetimibe
Ezetimibe is a lipid lowering drug that inhibits the intes-
tinal absorption of cholesterol withouth significant inter-
action with P-450 cytocromes [64].
Studies on PLWHIV with dyslipidemia evaluated ezeti-
mibe alone or in combination with statins. Ezetimibe
alone showed a statistically significant reduction of LDL-
cholesterol (ranging from 5.3% to 20.4%) but no signifi-
cant change in HDL-cholesterol and triglycerides [65, 66].
The studies that added ezetimibe to a stable statin therapy
showed a significant reduction of total cholesterol (ran-
ging from −12.9% to −21%) and LDL-C (from 20.8% to
Table 6 The ACC/AHA guideline statin dose classification
Reduction of LDL-C level
50% 30–50% ≤30%
Intensity dose
(dose of statin
daily)
High Atorvastatin 20–40 mg
Rosuvastatin 20–40 mg
Moderate Atorvastatin 10–20 mg
Rosuvastatin 5–10 mg
Simvastatin 20–40 mg
Pravastatin 40–80 mg
Fluvastatin 80 mg
Pitavastatin 2–4 mg
Low Simvastatin 10 mg
Pravastatin 10–20 mg
Lovastatin 20 mg
Fluvastatin 20–40 mg
Pitavastatin 1 mg
LDL-C, low-density lipoprotein-cholesterol
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35%) with conflicting results about HDL and triglycerides.
Ezetimibe represents an affordable choice in statin-
intolerant patient and a good option to intensify statin
therapy with a very low toxicity profile [67–73].
PCSK9 inhibitors
Proprotein convertase subtilisin/kexin type 9 (PCSK9)
gene, discovered in 2003, encode for a serine protease
protein that plays a central role for the regulation of
cholesterol metabolism by targeting the LDL receptor
(LDLR) for the degradation in the liver [74]. Gain-of-
functions mutations in PCSK9 are one of the genetic
causes of autosomal dominant hypercholesterolemia
[75]. On the other hand, low-of-function mutations are
associated with lower levels of LDL-C and reduced rates
of coronary artery disease [76].
Several strategies have been developed to block PCSK9
function including binding of plasma PCSK9 with neu-
tralizing monoclonal antibodies (mAbs) or targeting the
intracellular PCSK9 by antisense oligonucleotides or
small interfering RNA. Up to date the most studied and
clinically advanced approach to PSCK9 inhibition is the
use of mAbs.
Two mAbs (alirocumab and evolocumab) have been
recently approved by the European Medicines Agency
for the use in subjects with familial hypercholesterol-
emia, in patients who failed to achieve acceptable lipid
control although an optimal lipid lowering therapy and
in those intolerant to statins.
Efficacy and tolerability of alirocumab and evolocumab
in the general population has been evaluated in different
studies, as reported in Table 7 [77–85].
Considering the high efficacy of PCSK9 inhibitors in
reducing LDL-C levels when used alone or in combin-
ation with a statin, their use in HIV-infected subjects
may help to control cholesterol levels and probably to
reduce the risk of MACE in this patients’ population.
Unfortunately to date, no data on the efficacy of evolo-
cumab and alirocumab among HIV-infected subjects are
available. However, a forthcoming randomized trial
(NCT02833844) will evaluate safety, tolerability, and effi-
cacy on LDL-C of evolocumab in 450 subjects with HIV
and with hyperlipidemia and/or mixed dyslipidemia.
Start date is scheduled on May 2017.
Drugs for the treatment of hypertriglyceridemia
Isolated hypertriglyceridemia is rare in the setting of
PLWHIV on cART in the modern era, the lipid profile
usually shows a mixed dyslipidemia [83, 84]. The role of
hypertrigliceridemia in cardiovascular disease is still de-
bated [85, 86] and the treatment is reccomended for se-
vere cases (e.g. triglycerides >500 mg/dl) especially for
the risk of acute pancreatitis [87].
Fibrates
Fibrates represent the first choice for treatment of
hypertriglyceridemia in HIV infected patients. They bind
and regulate nuclear receptor peroxisome proliferator
activator receptor-α (PPAR- α) and regulate gene expres-
sion [88]. Fenofibrate is the most commonly used fibrate
in HIV-associated dyslipidemia both for the once daily
dose and for the reduced interaction with statin with a
lower risk of rhabdomyolisis [89, 90]. Studies on HIV-
population evaluating fenofibrate showed a significant
reduction of triglycerides (from 18% to 58%) depending
on cART regimen, study design, and on grade of
hypertriglyceridemia [91]. An observational analysis in-
cluding 80 patients with HIV infection on fenofibrates
with a mean baseline triglycerides value of 347 mg/dl
showed a reduction of 18% of triglycerides [91]. A ran-
domized trial evaluating fish-oil therapy versus fenofi-
brate enrolling 50 patients with HIV infection in each
arm demonstrated a reduction of 58% of triglycerides in
fenofibrate arm with a median baseline of triglycerides
of 694 mg/dl [92]. Few studies evaluated the use of
fibrates and statins in HIV associated dyslipidemia [93]
and they demonstrated an higher efficacy as reported in
general population [94]. An important issue is the in-
creased renal toxicity associated with the use of fibrates
and statins that should be considered [93].
Fish oil
Omega 3 fatty acids have a good safety profile and have
been used in HIV-associated dyslipidemia. They demon-
strated a reduction of triglycerides ranging from 7% to
38% in a retrospective analysis of 73 patients on PI based
regimen vs a non-nucleoside reverse-transcriptase inhibi-
tors (NNRTI) regimen respectively [91]. In three recent
randomized trial including less than 50 patients per arm a
triglycerides reduction of 9–48% was observed [92–98].
The association with statins results in a more favorable
lipid profile with a very low toxicity [99, 100] but the
introduction of ezetimibe that shows an higher efficacy
has limited the use of omega 3 only for patients with a
low-moderate dyslipidemia and isolated hypertrigliceride-
mia. Another concern is the higher dose (2–4 g/die)
needed to obtain a real efficacy with development of side
effects such as flatulence.
Studies evaluating fibrates and fish oil in mixed dyslip-
idemia and isolated trigliceridemia are summarized In
Table 8.
Tesamorelin
HIV-infected subjects, particularly those treated with
antiretroviral therapy, may experience significant accu-
mulation of visceral fat. The increased visceral adiposity
has been associated with dyslipidemia and with reduc-
tions in growth hormone (GH) secretion [101–103].
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Table 7 Efficacy and safety of evolocumab and alirocumab in different studies performed in the general population
Study Design Enrolled patients Efficacy results Safety results reference
Meta-analysis on Phase 2 or 3
randomized, controlled trials (RCTs)
comparing treatment using PCSK9
antibodies with no anti-PCSK9
therapy in adults with
hypercholesterolemia.
Twenty-four RCTs
comprising 10,159
patients were included.
Treatment with PCSK9 antibodies led
to marked reductions in LDL-C
(mean difference, −47.49% [95% CI,
−9.64% to −25.35%]; P < 0.001] and
it reduced all-cause mortality ([OR],
0.45 [CI, 0.23 to 0.86]; P = 0.015;
heterogeneity P = 0.63; I2 = 0%) and
cardiovascular mortality (OR, 0.50
[CI, 0.23 to 1.10]; P = 0.084;
heterogeneity P = 0.78; I2 = 0%).
The overall incidence of serious
adverse events was 9.26% (573 of
6187) among patients treated with
PCSK9 antibodies and 7.73% (307 of
3972) among patients who were not
treated with PCSK9 antibodies (OR,
1.01 [CI, 0.87 to 1.18]; P = 0.879;
heterogeneity P = 0.98; I2 = 0%).
[77]
Meta-analysis to evaluate the
safety and efficacy of anti-PCSK9
antibodies in randomized,
controlled trials (RCTs).
Twenty-five RCTs
encompassing 12,200
patients were included
Evolocumab treatment significantly
reduced LDL-C by −54.6% and by
absolute −78.9 mg/dl versus placebo,
and by −36.3% versus ezetimibe.
Alirocumab lowered LDL-C by
−52.6% versus placebo, by −29.9%
versus ezetimibe.
Alirocumab was associated with
an increased rate of injection-site
reactions (RR: 1.48, 95% CI: 1.05 to
2.09, P = 0.02)
[78]
ODYSSEY FH I and II:
two randomized, double-blind
studies to assess long-term
alirocumab in patients with
heterozygous familial
hypercholesterolaemia
ODYSSEY FH I, n = 486;
FH II, n = 249
subjects
Mean LDL-C levels decreased from
3.7 mmol/L (144.7 mg/dL) at baseline
to 1.8 mmol/L (71.3 mg/dL; 257.9%
vs. placebo) at Week 24 in patients
randomized to alirocumab in FH I
and from 3.5 mmol/L (134.6 mg/dL)
to 1.8 mmol/L (67.7 mg/dL; 251.4%
vs. placebo) in FH II (P, 0.0001).
Adverse events resulted in
discontinuation in 3.4% of
alirocumab-treated patients in FH I
(vs. 6.1% placebo) and 3.6% (vs.
1.2%) in FH II. Rate of injection site
reactions in alirocumab-treated
patients was 12.4% in FH I and
11.4% in FH II (vs. 11.0 and 7.4%
with placebo).
[80]
TESLA Part B:
randomised, double-blind,
placebo-controlled phase 3 trial of
subjects with homozygous familial
hypercholesterolaemia, randomly
allocated to receive subcutaneous
evolocumab 420 mg or placebo
every 4 weeks for 12 weeks.
50 eligible patients Compared with placebo,
evolocumab significantly reduced
LDL cholesterol at 12 weeks by
30·9% (95% CI −43·9% to −18·0%;
p < 0·0001).
Treatment-emergent adverse events
occurred in ten (63%) of 16 patients
in the placebo group and 12 (36%)
of 33 in the evolocumab group.
[81]
ODYSSEY LONG TERM:
randomized trial involving
subjects to receive
alirocumab (150 mg) or placebo
for 78 weeks.
2341 patients at high
risk for cardiovascular
events who had LDL
cholesterol levels of
70 mg per deciliter or
more and were
receiving treatment
with statins at the
maximum tolerated
dose
At week 24, the difference between
the alirocumab and placebo groups
in the mean percentage change
from baseline in calculated LDL
cholesterol level was −62%
(P < 0.001)
In a post hoc analysis, the rate of
major adverse cardiovascular events
was lower with alirocumab than with
placebo (1.7% vs. 3.3%; hazard ratio,
0.52; 95% confidence interval, 0.31 to
0.90; nominal P = 0.02).
The alirocumab group, as compared
with the placebo group, had higher
rates of injection-site reactions (5.9%
vs. 4.2%), myalgia (5.4% vs. 2.9%),
neurocognitive events (1.2% vs.
0.5%), and ophthalmologic events
(2.9% vs. 1.9%).
[82]
The GAUSS-2 trial:
12-week, double-blind study of
randomized patients (2:2:1:1) to
evolocumab 140 mg every two
weeks (Q2W) or evolocumab
420 mg once monthly (QM) both
with daily oral placebo or
subcutaneous placebo Q2W or
QM both with daily oral ezetimibe
10 mg.
307 patients At week 12, evolocumab reduced
LDL-C from baseline by 53% to 56%,
corresponding to treatment
differences versus ezetimibe of 37%
to 39% (p < 0.001).
Muscle adverse events occurred in
12% of evolocumab-treated patients
and 23% of ezetimibe-treated pa-
tients. Treatment-emergent adverse
events and laboratory abnormalities
were comparable across treatment
groups.
[83]
OSLER Study:
two open-label, randomized trials
of patients who had completed 1
of 12 phase 2 or 3 studies of
evolocumab.
4465 eligible patients
randomly assigned
to receive either
evolocumab plus
standard therapy or
standard therapy alone.
As compared with standard therapy
alone, evolocumab reduced the level
of LDL-C by 61%, from a median of
120 mg per deciliter to 48 mg per
deciliter (P < 0.001).
The rate of cardiovascular events at
1 year was reduced from 2.18% in
the standard-therapy group to 0.95%
in the evolocumab group (hazard
Neurocognitive events were
reported more frequently in the
evolocumab
group. The risk of adverse events,
including neurocognitive events, did
not vary significantly according to
the achieved level of LDL
cholesterol
[84]
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The use of tesamorelin, a synthetic analog of human
growth hormone-releasing factor, decreases visceral adi-
pose tissue (VAT) and concomitantly reduces tryglicer-
ides, total cholesterol concentration and non-HDL-C
among HIV-infected subjects.
In a study by Falutz et al. [104] the measure of VAT
decreased by 15.2% in the tesamorelin group and in-
creased by 5.0% in the placebo group; the levels of tri-
glycerides decreased by 50 mg per deciliter and
increased by 9 mg per deciliter, respectively, and the ra-
tio of total cholesterol to HDL cholesterol decreased by
0.31 and increased by 0.21, respectively (P < 0.001 for
all comparisons).
In another study by the same author [105] the use of
tesamorelin reduced trygliceride levels by approximately
40 mg/dL in pooled analysis of the ITT population.
Similarly a study by Stanley et al. showed that individ-
uals who responded to tesamorelin (defined as a ≥ 8%
reduction in VAT) experienced significantly greater im-
provements in levels of tryglicerides compared to nonre-
sponders [106].
The observed reduction in tryglicerides is probably
mediated at least in part by the direct effect of tesamore-
lin in increasing GH levels and probably by a possible
role of VAT reduction itself in decreasing tryglicerides
levels [107].
Table 7 Efficacy and safety of evolocumab and alirocumab in different studies performed in the general population (Continued)
ratio in the evolocumab group, 0.47;
95% CI, 0.28 to 0.78; P = 0.003).
FOURIER study:
randomized, double-blind,
placebo-controlled trial of patients
with atherosclerotic cardiovascular
disease and LDL cholesterol levels
of 70 mg per deciliter or higher
who were receiving statin therapy.
The primary efficacy end point was
the composite of cardiovascular
death, myocardial infarction, stroke,
hospitalization for unstable angina,
or coronary revascularization
27,564 patients were
randomly assigned to
receive evolocumab or
matching placebo as
subcutaneous injections
At 48 weeks, mean percentage
reduction in LDL cholesterol levels
with evolocumab, as compared with
placebo, was 59% (P < 0.001).
Relative to placebo, evolocumab
treatment significantly reduced the
risk of the primary end point (1344
patients [9.8%] vs. 1563 patients
[11.3%]; hazard ratio, 0.85; 95%
confidence interval [CI], 0.79 to 0.92;
P < 0.001
No significant difference between
the study groups with regard to
adverse events (including new-onset
diabetes and neurocognitive events),
with the exception of injection-site
reactions, which were more
common with evolocumab (2.1%
vs. 1.6%).
[85]
Table 8 studies evaluating fibrates and fish oil in mixed dyslipidemia and isolated trigliceridemia
Drugs Sample size Study Design Reduction of TRG (±SD or IQR) References
FO vs Fenofibrate vs
Gemfibrozil vs Atorvastatin
76 vs 80 vs 46 vs 291
(HIV-infected).
Observational/ quasi-
experimental pre/post design.
Median period of observation:
5 months
FO: −45 mg/dl (−80 to −11)
Fenofibrates vs FO: −49 mg/dl
(−108 to 11)
Gemfibrozil vs FO: - 80 mg/dl
(−150 to −10)
Atorvastatin vs FO: −33 mg/dl
(−81 to 15)
[140]
Fenofibrate 55 with Lipodystrophy with
severe Hypertriglyceridemia
(TRG > 500 mg/dl) [HIV-POS]
Observational/Prospective
Observation period =
6 months
Mean change:-335 mg/dl [90]
FO vs Fenofibrate vs
FO + Fenofibrate
50 vs 50, if no response at
week 10 switch to combination
therapy; 72 pts. switched.
(HIV-infected)
Randomized-Open label
Study duration: 18 weeks
FO = 46% vs Fenofibrate (58%)
vs FO + Fenofibrate (65%)
[95]
Fenofibrate vs pravastatin
vs Fenofibrate + pravastatin
88 vs 86, if no response at week
12 switch to combination therapy
(most patients switched) [HIV-infected]
Randomized-Open label
Study duration: 48 weeks
Median change: −144 mg/dl
(−1492 to 927 fenofibrate)
vs −66 (−899 to 1567 prevastatin)
[89]
FO 41 (HIV-infected) Randomized-Open label
Study duration: 12 weeks
Mean change: 63.2 ± 86.9 mg/dl
mg/dl
[92]
FO 48 (HIV-infected) Randomized-placebo-
controlled
Study duration: 8 weeks
Median decrease: −34 (−149–9.5)
mg/dL
[97]
FO + simvastatin 254 (uninfected) Randomized-Open label
Study duration: 8 weeks
Mean change: 29% (FO +
simvastatin) vs 6% (simvastatin)
[97]
FO + simvastatin 59 with Coronary heart disease
already on simvastatin (uninfected)
Randomized, Study duration:
24 weeks + 24 weeks
Mean change: 20–30% [98]
TRG, Triglycerides; FO, Fish Oil; SD, standard deviation; IQR, interquartile range; pts., patients
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Tesamorelin is usually well tolerated. The most com-
monly reported adverse events (>10%) were injection site
erythema, pruritus, headache and arthralgia [108].
Fat redistribution in HIV-infected subjects
Long-term ART use has been associated with the occur-
rence of lipodystrophy, a medical condition character-
ized by an abnormal fat redistribution [109].
Fat redistribution among HIV-infected subjects is usu-
ally classified in specific entities: lipoatrophy, lipohyper-
trophy and mixed syndromes [110, 111].
Lipoatrophy (LA) is the loss of subcutaneous periph-
eral fat usually at the face, buttocks and limbs [112, 113]
and has been associated with the use of thymidine ana-
logues (zidovudine and stavudine). Decline in the use of
these drugs resulted in a significant decrease in severe
LA prevalence [114].
On the contrary, lipohypertrophy (LH) that is the accu-
mulation of visceral and central fat in the abdomen, anter-
ior neck, dorsocervical region (“buffalo hump”), trunk and/
or breasts [115, 116], still occur in some treated patients
[117]. In the general population, increased visceral adipose
tissue (VAT) increases the risk of type II diabetes mellitus
(T2DM), cardiovascular disease (CVD) and overall mortal-
ity. In HIV-infected subjects VAT has been also independ-
ently associated with mortality [118]. The main hypothesis
regarding the development of LH suggests that alterations
in peripheral adipocytes result in an increased levels of cir-
culating fatty acid (CFA). The CFA are then deposited in
VAT due to the higher rate of lipid turnover and uptake in
visceral adipocytes [119]. These alterations in metabolism
of adipocyte may be secondary to a direct action of HIV it-
self via viral protein Vpr or to a deleterious effect of cART
[115, 120]. Moreover, ectopic fat deposition is associated
with inflammation and adverse metabolic impact beyond
that seen with generalized obesity [121]. Associations
between intra-abdominal VAT and increased metabolic
disease risk (including CVD) are well described both in
cross-sectional and longitudinal studies [122–124]. In a
cross-sectional study of nearly 600 HIV-infected men on
stable ART, greater VAT, liver fat, and epicardial fat were
independently associated with CVD after adjusting for trad-
itional CVD risk factors [125]. PLWHIV in the CHARTER
study with increased visceral adiposity had significantly
worse neurocognitive function. Furthermore, an association
between higher IL-6 levels and poorer neurocognitive func-
tion was found only among those with the largest waist cir-
cumferences, supporting a link between visceral adiposity,
inflammation, and neurocognitive function in HIV-infected
persons [126].
Conclusions
Cardiovascular disease and dyslipidemia among PLWHIV
remain nowadays challenging issues. Prevention of CVD
risk is the first and essential step of medical intervention
on these patients. The lifestyle modification and the edu-
cation on healthy dietary practices are fundamental tools
for reducing CVD risk.
Current antiretroviral regimens are easier to take, bet-
ter tolerated, and more effective than regimens used in
the past, therefore optimization of ART in terms of side
effects tolerability is essential, since HIV infection re-
quires life-long therapy. The optimal treatment strat-
egies are based on the assumption that not all
antiretroviral agents have similar toxicities. PI/ritonavir
may cause dyslipidemia and lipodystrophy, while INI
have a minimal impact on lipids profile, and not re-
ported evidence of lipodystrophy. There is still much to
discover with the introduction of new drugs in clinical
practice: dolutegravir, TAF and cobicistat.
Statins are the cornerstone of the treatment of hyper-
cholesterolemia. They slow the progression or even pro-
mote regression of coronary atherosclerosis and also
could exert a wide-reaching anti-inflammatory and im-
munomodulatory effect. The 2013 ACC/AHA guidelines
introduced a new CV risk calculator different from the
ESC and EAS Guidelines for the management of dyslipi-
daemia and identified 4 groups of patients who should
be treated with a statin. These guidelines classify statin
doses by 3 levels of intensity based on their ability to
lower LDL-C levels in the general population. At
present, the debate between American and European
guidelines is still open and, also considering the inde-
pendent risk factor represented by HIV, specific guide-
lines for HIV-infected persons are warranted.
Another effective drug for the hypercholesterolemia is
ezetimibe that markedly reduces the intestinal absorption
of cholesterol. In HIV-infected subjects, ezetimibe already
showed to be effective in reducing the total cholesterol
and LDL-C levels when used alone or in combination with
rosuvastatin. PCSK9 inhibitors, MTP inhibitors, antisense
oligonucleotide against apolipoprotein B, adenosine Tri-
phosphate Citrate Lyase Inhibitors are experimental and
sometimes promising new classes of drugs for the treat-
ment of hypercholesterolemia.
Fibrates represents the first choice for treatment of
hypertriglyceridemia in HIV infected patients. Few studies
evaluated the use of fibrates and statins in HIV associated
dyslipidemia and demonstrated an higher efficacy as re-
ported in the general population. Omega 3 fatty acids have
a good safety profile and has been used in HIV-associated
dyslipidemia, but their efficacy is limited to patients with a
low-moderate dyslipidemia and isolated hypertrigliceride-
mia. Other drugs for hypertrigliceridemia are: acipimox,
that showed a low efficacy; niacin that, in spite of its effi-
cacy can induce insulin resistance and hepatotoxicity; and
tesamorelin that has demonstrated a good efficacy in low-
ering triglycerides and total cholesterol.
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